Samsung Biologics signs $1.4 bn CMO deal with European pharma

Quick Summary:

South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a contract manufacturing organization (CMO) deal with an unidentified European biopharmaceutical firm.

Samsung Biologics said it broke the record just over three months after signing a $1.1 billion contract with an Asian pharmaceutical company last October.

Samsung Biologics is building a fifth plant with an annual production capacity of 180,000 liters, which is expected to be operational in April.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South Korea

Topics: Last Company Biologics Contract Deal Signs Largest Year Korea Samsung Orders

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-14 @ 10:45:16 (13 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 143 words

Reading Time: 1 minutes read

Sentences: 16 lines

Sentence Length: 9 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 25136286

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 9 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 4 hours ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions